You are here

OMP-18R5

OncoMed Pharmaceuticals Presents Updated Phase 1a Data in Advanced Solid Tumor Patients for the First-in-Class WNT-Pathway-Targeting Antibody Vantictumab (OMP-18R5) at the European Cancer Congress 2013

Yahoo/GlobeNewsWire

Sun, 09/29/13 - 01:32 pm

neuroendocrine tumors